Short answer: yes — PT-141 is FDA approved, under the brand name Vyleesi, and it has been since 2019. But the approval is narrower than most vendor marketing implies, and the legal picture around the various ways PT-141 is sold has more layers than a yes or no. Here is the full status, current as of 2026.
The Approval: Vyleesi, June 2019
The FDA approved bremelanotide — the generic name for PT-141 — on June 21, 2019, under the brand name Vyleesi. It was only the second medication ever approved for hypoactive sexual desire disorder (HSDD) in women, following Addyi in 2015, and the first designed for on-demand use. The approval rested on the RECONNECT program: two placebo-controlled trials in over 1,200 premenopausal women.
What the Approval Covers — and What It Doesn't
The indication is precise: acquired, generalized HSDD in premenopausal women — low desire causing marked distress that isn’t explained by a medical or psychiatric condition, relationship problems, or medication effects. The label is equally explicit about what Vyleesi is not indicated for:
- Not for postmenopausal women — they were not in the pivotal trials.
- Not for men — despite years of research interest in male sexual dysfunction.
- Not to enhance sexual performance — the label rules this out by name. It is a treatment for a diagnosed disorder, not an enhancement product.
Any use outside that box is off-label territory — legal for a physician to prescribe in their judgment, but outside what the FDA evaluated.
Is Vyleesi Still on the Market in 2026?
Yes. The product has changed corporate hands over the years — developed by Palatin Technologies, licensed to AMAG, returned to Palatin in 2020, and now marketed by Cosette Pharmaceuticals — and it remains actively available in 2026 through telehealth prescribing and pharmacy home delivery, with a manufacturer program that brings a four-dose box to around $99 cash or as low as $0 with commercial coverage (typical 2026 figures). No generic exists: patent analysts place the earliest realistic generic entry years away, in the early 2030s.
So Is PT-141 "Legal"? The Three-Tier Answer
“PT-141” is sold in three very different forms, and their status differs:
| Form | Status | What That Means |
|---|---|---|
| Vyleesi (branded autoinjector) | FDA-approved prescription drug | Fully legal with a prescription; manufactured to pharmaceutical standards; the only form the FDA has evaluated for safety and efficacy |
| Compounded bremelanotide (pharmacy vials) | Prescription-dependent; not an FDA-approved product | Legally dispensed by licensed compounding pharmacies under compounding rules, but without FDA review of the finished product; quality varies by pharmacy |
| Research-vendor PT-141 (vials/nasal sprays) | Sold as not-for-human-use research material | The listing is legal as research chemistry; using it on yourself was never evaluated by anyone, and no screening for blood pressure, pregnancy, or interactions occurs |
The distinctions matter more for this compound than for most, because bremelanotide’s label carries real screening flags: a transient blood-pressure rise with every dose (making uncontrolled hypertension a no-go), possible lasting skin hyperpigmentation with overuse, a naltrexone interaction, and a stop-if-pregnant rule. Those are precisely the things a prescription pathway checks and a research-vial pathway doesn’t. Our sourcing guide covers the framework in depth.
What About Vyleesi vs "PT-141" Marketing?
Worth stating plainly: Vyleesi and PT-141 are the same molecule. When a clinic or vendor markets “PT-141 therapy” as something distinct from or superior to Vyleesi, that is branding, not chemistry. The meaningful differences between offerings are formulation, dose accuracy, quality control, and whether anyone with a license reviewed your health history — and on all four, the approved product is the benchmark the others are measured against. For how the compound actually performs and what to expect, see our complete PT-141 guide for women.